CED Member Viamet Pharmaceuticals is raising a third round of funding, according to an SEC filing.
According to the SEC filing, Viamet says it has raised $3 million and is seeking an additional $2.75 million to complete the round.
Six current investors have put additional money into the firm, which is backed by Durham-based CED Member Intersouth Partners.
Viamet is developing technology it calls Metallophile, designed to make drugs safer through the use of metalloenzme inhibitors.
Viamet was co-founded by UNC-Chapel Hill Chancellor Holden Thorpe.